Tipsheet
What matters at India’s listed companies
M&A · Pharmaceuticals · Micro cap

Ortin Global's open offer draws just 226 shares of 21.14 lakh target

The acquirer ends up with 1.24% stake instead of the 27.23% control sought. Public shareholders overwhelmingly rejected the ₹14.65 price, aborting the change of control.


Mkt cap₹14.03 cr
ROE0.00%
Debt / eq.0.13
226 shares Tendered out of 21.14 lakh targeted

What's new

  • Only 226 shares tendered in open offer for 26% stake, out of 21.14 lakh targeted.
  • Acquirer's stake rises to just 1.24% instead of intended 27.23%.
  • Total outlay was ₹3,311 against planned ₹3.09 crore.

Why this matters

The near-total rejection signals public shareholders found the price unattractive or lacked confidence in the acquirer. The takeover attempt stalls, leaving control unchanged and removing a potential catalyst for the nano-cap stock.

What we're watching

  • Whether the acquirer returns with a revised offer at a higher price.
  • Any management commentary on strategic direction post-offer.
  • Possible impact on stock liquidity and trading volumes.

The full read

Ortin Global's mandatory open offer wrapped up with virtually no takers. Of the 21.14 lakh shares targeted (representing a 26% stake), just 226 shares were tendered. The acquirer, Parveen Satija, paid a total of ₹3,311 for the deal instead of the planned ₹3.09 crore. Post-offer, his stake stands at a mere 1.24%, not the 27.23% that would have given him control. Public shareholders rejected the ₹14.65 price outright. Hardly a vote of confidence. For a nano-cap with a ₹14 crore market cap, the failure to secure even a fraction of the targeted stake is damning. It removes the expected catalyst of a new controlling shareholder and leaves the company's strategic direction uncertain. The open question is whether the acquirer will return with a higher bid or walk away.

Questions answered

How many shares were tendered in Ortin Global's open offer?
Only 226 shares out of the targeted 21.14 lakh shares were tendered, representing a 0.1% acceptance rate.
What was the offer price and why did shareholders reject it?
The offer price was ₹14.65 per share. The low acceptance suggests shareholders considered the price inadequate or lacked confidence in the acquirer.
What is the acquirer's stake after the offer?
Post-offer, Parveen Satija holds just 1.24% of Ortin Global, far below the 27.23% intended after full subscription.
Will the acquirer launch another open offer?
The filing does not indicate future plans. A revised offer at a higher price or a different approach may be needed to gain control.
Does this change the company's control structure?
No, the existing control structure remains unchanged as the acquirer failed to secure a meaningful stake.
Mentioned: Parveen Satija · Ortin Global
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Ortin Global Ltd.

Pharmaceuticals
₹14 cr

Latest quarter · Jun 2012

Sales₹16 cr
Net profit₹0 cr
Op. margin+13.1%
EPS₹0.26

Strength & growth

Debt / equity0.13×
Current ratio2.15×
Sales CAGR−38.8%